Lonza has extended a supply agreement with Bristol-Myers Squibb to make the active ingredient of Bristol-Myers’ rheumatoid arthritis drug, Orencia, through 2013. Financial details of the agreement were not disclosed.

The extension of the deal, for manufacturing the biologic agent abatacept at Portsmouth, NH, will give BMS more production capacity for Orencia, Lonza said in a statement.